[Ganli Pharmaceutical: Subsidiary obtained clinical trial approval for new indications of GZC8072 tablets] On September 3, Ganli Pharmaceutical (603087.SH) announced that the company's wholly-owned subsidiary Ganli Pharmaceutical Shandong recently received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration, agreeing to conduct clinical trials for the indication of type 2 diabetes for the drug under development GZC8072 tablets. The drug is a new generation of biased ultra-long-acting peptide oral weekly preparation independently developed by the company. No similar GLP-1 oral weekly preparation tablet has been approved for marketing in the world. As of June 30, 2026, the cumulative R&D investment in this project was 66.3326 million yuan.